{"entity":{"id":"paper-barretina-nat-genet","kind":"paper","name":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","aka":[],"tldr":"Paper cited by one target page, indexed on Europe PMC as PubMed record 20601955 and published in Nature Genetics; the citing page links this DOI, which is how the record was matched.","summary":"Soft-tissue sarcomas, which result in approximately 10,700 diagnoses and 3,800 deaths per year in the United States, show remarkable histologic diversity, with more than 50 recognized subtypes. However, knowledge of their genomic alterations is limited. We describe an integrative analysis of DNA sequence, copy number and mRNA expression in 207 samples encompassing seven major subtypes. Frequently mutated genes included TP53 (17% of pleomorphic liposarcomas), NF1 (10.5% of myxofibrosarcomas and 8% of pleomorphic liposarcomas) and PIK3CA (18% of myxoid/round-cell liposarcomas, or MRCs). PIK3CA mutations in MRCs were associated with Akt activation and poor clinical outcomes. In myxofibrosarcomas and pleomorphic liposarcomas, we found both point mutations and genomic deletions affecting the tumor suppressor NF1. Finally, we found that short hairpin RNA (shRNA)-based knockdown of several genes amplified in dedifferentiated liposarcoma, including CDK4 and YEATS4, decreased cell proliferation. Our study yields a detailed map of molecular alterations across diverse sarcoma subtypes and suggests potential subtype-specific targets for therapy.\n\nIndexed on Europe PMC as PubMed record 20601955 (DOI 10.1038/ng.619). Matched by DOI alone: one target page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Nat Genet 2010","url":"https://doi.org/10.1038/ng.619"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/20601955/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/20601955"}],"tags":["europepmc-ingest"],"related":["mdm2"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-genetics"],"dependsOn":[],"notes":[],"journal":"Nature Genetics","year":2010,"doi":"10.1038/ng.619","pmid":"20601955","authors":"Barretina J, Taylor BS, Banerji S, et al.","paperType":"observational","findings":[],"whatItMeans":"One target page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.","caveats":["Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-barretina-nat-genet/","neighbours":{"target":[{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/"}],"journal":[{"id":"nature-genetics","kind":"journal","name":"Nature Genetics","route":"/journals/nature-genetics/"}]}}